Back to Search
Start Over
Amphotericin B and coccidioidomycosis.
- Source :
-
Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2007 Sep; Vol. 1111, pp. 434-41. Date of Electronic Publication: 2007 May 18. - Publication Year :
- 2007
-
Abstract
- Prior to the 1950s no effective therapy for coccidioidomycosis existed. The advent of amphotericin B ushered in the therapeutic era for coccidioidomycosis. Until this time amphotericin B and its lipid congeners have been regarded as the "gold standard" of therapy for severe pulmonary and disseminated coccidioidomycosis. The availability of azoles and later triazoles for the past three decades have relegated the amphotericins into a rescue mode, used mainly in widely disseminated cases, azole intolerance, or when there are contraindications to Azoles, such as pregnancy. In meningitis the intrathecal use of amphotericin B is still used frequently by some clinicians alone or with a triazole. The newer lipid preparations, while more expensive, have significantly reduced toxicity, particularly nephropathy.
- Subjects :
- Antifungal Agents therapeutic use
Coccidioides metabolism
Deoxycholic Acid therapeutic use
Drug Combinations
Female
Humans
Kidney Diseases etiology
Lipids chemistry
Pregnancy
Treatment Outcome
Triazoles therapeutic use
Amphotericin B therapeutic use
Coccidioidomycosis drug therapy
Meningitis drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0077-8923
- Volume :
- 1111
- Database :
- MEDLINE
- Journal :
- Annals of the New York Academy of Sciences
- Publication Type :
- Academic Journal
- Accession number :
- 17513463
- Full Text :
- https://doi.org/10.1196/annals.1406.019